NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia
· Delayed Price · Currency is AUD 0.105
+0.005 (5.00%)
Mar 10, 2026, 9:59 AM AEST
ASX:NSB Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Cash & Equivalents | 1.11 | 7.27 | 4.95 | 4.91 | 7.22 | 14.16 | Upgrade
|
| Cash & Short-Term Investments | 6.36 | 7.27 | 4.95 | 4.91 | 7.22 | 14.16 | Upgrade
|
| Cash Growth | 41.48% | 46.66% | 0.86% | -31.93% | -49.05% | 330.88% | Upgrade
|
| Accounts Receivable | 0.12 | 0.1 | 0.05 | 0.04 | 0.12 | 0.05 | Upgrade
|
| Receivables | 0.12 | 0.1 | 0.05 | 0.04 | 0.12 | 0.05 | Upgrade
|
| Prepaid Expenses | 0.1 | 0.03 | 0.04 | 0.05 | 0.06 | 0.22 | Upgrade
|
| Total Current Assets | 6.57 | 7.4 | 5.04 | 5.01 | 7.4 | 14.43 | Upgrade
|
| Property, Plant & Equipment | 0 | 0 | 0.01 | 0.01 | 0.02 | 0.03 | Upgrade
|
| Other Intangible Assets | 10.09 | 9.57 | 0.39 | 0.27 | 0.32 | 0.37 | Upgrade
|
| Total Assets | 16.66 | 16.96 | 5.44 | 5.29 | 7.74 | 14.83 | Upgrade
|
| Accounts Payable | 0.19 | 0.15 | 0.08 | 0.59 | 2.17 | 0.18 | Upgrade
|
| Accrued Expenses | 0.02 | - | 0 | 0.01 | 0.05 | 0.05 | Upgrade
|
| Total Current Liabilities | 0.21 | 0.15 | 0.09 | 0.6 | 2.22 | 0.22 | Upgrade
|
| Total Liabilities | 0.21 | 0.15 | 0.09 | 0.6 | 2.22 | 0.22 | Upgrade
|
| Common Stock | 34.26 | 34.26 | 25.52 | 25.27 | 25.27 | 25.27 | Upgrade
|
| Retained Earnings | -24.98 | -23.28 | -22.04 | -22.99 | -22.6 | -12.18 | Upgrade
|
| Comprehensive Income & Other | 7.18 | 5.84 | 1.87 | 2.41 | 2.84 | 1.5 | Upgrade
|
| Shareholders' Equity | 16.45 | 16.81 | 5.35 | 4.69 | 5.52 | 14.6 | Upgrade
|
| Total Liabilities & Equity | 16.66 | 16.96 | 5.44 | 5.29 | 7.74 | 14.83 | Upgrade
|
| Net Cash (Debt) | 6.36 | 7.27 | 4.95 | 4.91 | 7.22 | 14.16 | Upgrade
|
| Net Cash Growth | 41.48% | 46.66% | 0.86% | -31.93% | -49.05% | 330.88% | Upgrade
|
| Net Cash Per Share | 0.03 | 0.05 | 0.03 | 0.03 | 0.05 | 0.10 | Upgrade
|
| Filing Date Shares Outstanding | 332.58 | 332.58 | 144.6 | 143.47 | 143.47 | 143.47 | Upgrade
|
| Total Common Shares Outstanding | 332.58 | 332.58 | 144.6 | 143.47 | 143.47 | 143.47 | Upgrade
|
| Working Capital | 6.37 | 7.25 | 4.96 | 4.41 | 5.18 | 14.2 | Upgrade
|
| Book Value Per Share | 0.05 | 0.05 | 0.04 | 0.03 | 0.04 | 0.10 | Upgrade
|
| Tangible Book Value | 6.37 | 7.25 | 4.96 | 4.42 | 5.2 | 14.23 | Upgrade
|
| Tangible Book Value Per Share | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | 0.10 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.